Irinotecan is a topoisomerase I inhibitor that binds to CCR9 protein (binding affinity: −17.1 kcal/mol) and has also been suggested as a potential candidate therapy to counter cytokine storms in critically ill COVID-19 patients34. Here, CCR9 is linked to COVID-19.